Merck

Merck

Prezzo: 119.05

Società e modello di business

Merck & Co., Inc. is a global healthcare company that develops and manufactures pharmaceuticals, vaccines, biologics, and animal health products. Its core products include treatments for cancer, diabetes, and infectious diseases, with significant revenue generated from its oncology and vaccine segments. The company also focuses on research and development to innovate new therapies and improve existing ones.

Profilo di investimento

The stock presents a balanced investment profile, appealing to investors seeking a combination of growth and income through dividends. With a moderate dividend yield and a focus on innovation, it may attract those interested in stable returns while also considering potential capital appreciation.

Sito ufficiale

Metriche fondamentali (sperimentale)

EPS (TTM) — utile per azione degli ultimi 12 mesi, $
3.56 OK
Ricavi QoQ — crescita dei ricavi trimestre su trimestre
-0.2%
Sorpresa EPS
1.5% in linea
Volatilità 20g
2.1% stabile
Rendimento dividendo
3.5% moderato ultima data ex-dividendo: 2026-06-15
Dati FMP / FinFeed aggiornati: 2026-06-09
Racc.: Compra Potenziale: 67 Rischio: 40 Aggiornato: 2026-06-13 02:52
Come funziona la raccomandazione
Perché l'AI la pensa così:
Stable dividend, but mixed momentum signals present uncertainty.

Traccia in portafoglio

Grafico prezzo

Raccomandazione AI Previsione analista Evento calendario Segnale positivo Segnale negativo Neutrale / aggiornamento Mantieni / informativo B My buy S My sell
Cambiamenti di raccomandazione AI
Data Prima Dopo Motivo
2026-06-09 02:45 Mantieni Compra Stable dividend, moderate growth, cautious market sentiment.
2026-06-01 02:45 Compra Mantieni Solid dividend yield, but mixed momentum signals.
2026-05-24 02:45 Mantieni Compra Strong momentum and solid dividend yield support growth.
Previsioni analisti
Data Analista Action Target Prezzo allora
2026-06-02 10:48 Guggenheim Aggiorna — → 140 115.21
2026-05-01 16:03 Morgan Stanley Target alzato 109 → 112 112.47
2026-03-12 11:05 Wells Fargo Target alzato — → 150 116.22
Merck Redwire Eli Lilly

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.